AMICUS THERAPEUTICS INC. - COMMON STOCK

Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023

29 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer

21 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom

15 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates

08 Aug 2023 06:00:01 By Nasdaq GlobeNewswire

Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023

31 Jul 2023 06:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union

27 Jun 2023 06:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates

10 May 2023 06:00:02 By Nasdaq GlobeNewswire

Amicus Therapeutics to Present at the Bank of America 2023 Health Care Conference

02 May 2023 06:00:01 By Nasdaq GlobeNewswire

Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023

01 May 2023 06:00:01 By Nasdaq GlobeNewswire

Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease

26 Apr 2023 12:00:33 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease

27 Mar 2023 06:00:09 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates

01 Mar 2023 06:00:02 By Nasdaq GlobeNewswire

Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

27 Feb 2023 06:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023

22 Feb 2023 16:00:08 By Nasdaq GlobeNewswire

Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023

14 Feb 2023 06:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023

13 Feb 2023 06:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference

08 Feb 2023 06:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook

09 Jan 2023 06:00:01 By Nasdaq GlobeNewswire

Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 06:00:01 By Nasdaq GlobeNewswire

Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease

16 Dec 2022 07:10:56 By Nasdaq GlobeNewswire